GKB Ophthalmics Ltd
GKB Ophthalmics Ltd (GKB) last reported results for the quarter ended Jun 2026, with sales of ₹33.04 crore and net profit of ₹1.85 crore. The stock last traded at ₹62, a market capitalisation of ₹31.3 crore, on a P/E of 8.51. Over the past 52 weeks the stock has ranged between ₹45.2 and ₹76.9. Figures are as of 6 Oct 2026 and are not real time.
GKB Ophthalmics Ltd share price and key metrics
- Current price
- ₹62
- Market cap
- ₹31.3 cr
- Stock P/E
- 8.51
- Book value
- ₹105
- ROE
- 3.28%
- ROCE
- 10.9%
- Dividend yield
- 0.00%
- 52w high / low
- 76.9/45.2
Metrics as of 6 Oct 2026. Not real time.
Track GKB Ophthalmics Ltd
Cruxal reads every GKB Ophthalmics Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
GKB Ophthalmics Ltd growth and returns
- 10 Years
- 13%
- 5 Years
- 21%
- 3 Years
- 25%
- TTM
- 30%
- 10 Years
- 11%
- 5 Years
- 77%
- 3 Years
- 138%
- TTM
- 147%
- 10 Years
- -7%
- 5 Years
- -9%
- 3 Years
- -14%
- 1 Year
- -5%
- 10 Years
- -2%
- 5 Years
- -2%
- 3 Years
- -5%
- Last Year
- 3%
GKB Ophthalmics Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹33.04 cr, up 2.3% from ₹32.31 cr a year earlier. Net profit turned positive at ₹1.85 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 26.14 | 25.8 | 31.02 | 32.31 | 30.17 | 56.79 | 29.79 | 33.04 |
| Expenses | 26.2 | 26.74 | 33.88 | 31.51 | 27.15 | 55.13 | 26.71 | 30.41 |
| Operating profit | -0.06 | -0.94 | -2.86 | 0.8 | 3.02 | 1.66 | 3.08 | 2.63 |
| OPM % | -0.23% | -3.64% | -9.22% | 2.48% | 10.01% | 2.92% | 10.34% | 7.96% |
| Other income | 0.28 | 0.48 | 0.35 | 0.21 | 0.37 | 0.57 | -0.68 | 0.73 |
| Interest | 0.55 | 0.63 | 0.63 | 0.77 | 0.66 | 0.73 | 0.52 | 0.51 |
| Depreciation | 0.77 | 0.77 | 0.8 | 0.8 | 0.82 | 0.82 | 0.8 | 0.8 |
| Profit before tax | -1.1 | -1.86 | -3.94 | -0.56 | 1.91 | 0.68 | 1.08 | 2.05 |
| Tax % | 5.45% | 2.69% | 4.82% | 14.29% | 3.66% | -4.41% | -3.70% | 9.76% |
| Net profit | -1.15 | -1.91 | -4.13 | -0.64 | 1.84 | 0.7 | 1.12 | 1.85 |
| EPS (₹) | -2.42 | -4.03 | -7.04 | -2.02 | 3.17 | 0.87 | 0.38 | 2.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
GKB Ophthalmics Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 76 | 78 | 57 | 59 | 57 | 71 | 75 | 88 | 109 | 149 | 150 |
| Operating profit | 2 | 1 | 1 | 2 | 2 | 5 | 4 | 1 | -3 | 9 | 10 |
| OPM % | 2.5% | 1.7% | 2.0% | 3.6% | 4.0% | 7% | 4.9% | 0.6% | -2.5% | 6% | 7% |
| Net profit | 3 | -1 | -1 | -2 | -1 | 2 | 0 | -3 | -7 | 3 | 6 |
| EPS (₹) | 6.24 | -2.34 | -2.37 | -3.65 | -1.81 | 2.52 | -0.34 | -5.57 | -13.97 | 2.22 | 6.42 |
TTM is the trailing twelve months to the most recent quarter.
GKB Ophthalmics Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 43 | 41 | 50 | 54 | 58 | 58 | 58 | 55 | 47 | 48 |
| Borrowings | 7 | 10 | 14 | 15 | 12 | 12 | 11 | 11 | 14 | 12 |
| Other liabilities | 28 | 28 | 25 | 28 | 32 | 35 | 38 | 43 | 59 | 68 |
| Total liabilities | 82 | 83 | 94 | 102 | 107 | 110 | 112 | 114 | 125 | 132 |
| Fixed assets | 18 | 18 | 26 | 26 | 24 | 23 | 19 | 18 | 17 | 15 |
| CWIP | 1 | 0 | 0 | 0 | 1 | 3 | 4 | 4 | 4 | 4 |
| Investments | 3 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Other assets | 60 | 64 | 68 | 75 | 80 | 82 | 87 | 91 | 102 | 111 |
| Total assets | 82 | 83 | 94 | 102 | 107 | 110 | 112 | 114 | 125 | 132 |
As reported by the company. Total assets equal total liabilities by construction.
GKB Ophthalmics Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3 | -3 | 4 | 3 | 7 | 5 | -3 | 4 | -3 | -4 |
| Cash from investing | 4 | 1 | -10 | -4 | -17 | -4 | 1 | -2 | 3 | 9 |
| Cash from financing | -1 | 1 | 13 | 4 | 3 | -2 | -2 | -2 | 1 | -6 |
| Net cash flow | -1 | 0 | 7 | 4 | -7 | -0 | -4 | 1 | -0 | -0 |
| Free cash flow | -9 | -5 | -6 | -0 | 1 | 0 | -2 | 2 | -6 | -5 |
| CFO / operating profit | -112% | -190% | 346% | 154% | 300% | 105% | -71% | 865% | 118% | -41% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
GKB Ophthalmics Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 3% | 0% | -2% | -1% | 3% | 4% | 2% | -1% | -6% | 11% |
| Debtor days | 118 | 129 | 150 | 155 | 125 | 100 | 134 | 117 | 85 | 110 |
| Inventory days | 225 | 223 | 289 | 301 | 349 | 307 | 298 | 245 | 250 | 189 |
| Days payable | 169 | 168 | 217 | 234 | 234 | 208 | 183 | 202 | 195 | 195 |
| Cash conversion cycle | 174 | 184 | 222 | 223 | 239 | 199 | 249 | 160 | 141 | 104 |
| Working capital days | 111 | 115 | 110 | 110 | 117 | 105 | 135 | 97 | 78 | 78 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
GKB Ophthalmics Ltd shareholding pattern
Promoters held 51.15% at Jun 2026, broadly unchanged since Jun 2025. FIIs 1.79%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.95% | 50.98% | 50.99% | 51.06% | 51.06% | 51.13% | 51.13% | 51.15% |
| FIIs | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% |
| Public | 47.28% | 47.23% | 47.23% | 47.16% | 47.17% | 47.09% | 47.09% | 47.07% |
| No. of shareholders | 2,510 | 2,539 | 2,538 | 2,550 | 2,601 | 2,661 | 2,634 | 2,557 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
GKB Ophthalmics Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find herewith Certificate under Regulation 74(5) of SEBI (Depositories and…
Read the full analysis - Pursuant to SEBI( Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the " Trading Window" for dealing/ trading in the shares of the Company shall remain closed ....Insider Trading / SASTlow impact
- GKB Ophthalmics Ltd. Concludes 44th AGM; Approves Key Management Re-appointments and Related Party Transaction Limits for FY 2026-27AGM/EGMlow impact
Cruxal's analysis: GKB Ophthalmics Ltd. has filed the minutes of its 44th Annual General Meeting held on…
Read the full analysis - GKB Ophthalmics Ltd. Announces Successful Conclusion of 44th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: GKB Ophthalmics Ltd. has successfully concluded its 44th Annual General Meeting held on…
Read the full analysis - GKB Ophthalmics Ltd. Concludes 44th Annual General Meeting; Focus Remains on Operational Efficiency Amid Global Macro HeadwindsAGM/EGMlow impact
Cruxal's analysis: GKB Ophthalmics Ltd. held its 44th Annual General Meeting on August 25, 2026, to address…
Read the full analysis - GKB Ophthalmics Ltd. Reports Unaudited Financial Results for Quarter Ended June 30, 2026Company Updatemedium impact
Cruxal's analysis: GKB Ophthalmics Ltd. has released its unaudited standalone and consolidated financial…
Read the full analysis - GKB Ophthalmics Reports Q1 FY27 Financial Results with Consolidated Net Profit of 1.85 croreResulthigh impact
Cruxal's analysis: GKB Ophthalmics Limited reported consolidated revenue from operations of 33.04 crore for…
Read the full analysis - GKB Ophthalmics reports Q1 FY27 results, challenges legal recovery proceedings, and closes non-performing subsidiaryBoard Meetinghigh impact
Cruxal's analysis: GKB Ophthalmics Limited reported Q1 FY27 standalone revenue of 6.40 crore and a net loss…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.